Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Cancer Drug Targets

Volume 12 Issue 7
ISSN: 1568-0096
eISSN: 1873-5576

 

   All Titles

  A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
  pp.857-872 (16) Authors: Z. Mihaly, Z. Sztupinszki, P. Surowiak, B. Gyorffy
 
 
      Abstract

Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus (an inhibitor of the mammalian target of rapamycin - mTOR) and pazopanib (a multi-targeted receptor tyrosine kinase inhibitor) are used in the first line of recurrent disease. A combination of bevacizumab (inhibition of angiogenesis) plus interferon α is also first-line therapy. Second line options include everolimus (another mTOR inhibitor) as well as tyrosine kinase inhibitors for patients who previously received cytokine. We review the results of clinical investigations focusing on survival benefit for these agents. Additionally, trials focusing on new agents, including the kinase inhibitors axitinib, tivozanib, dovitinib and cediranib and monoclonal antibodies including velociximab are also discussed. In addition to published outcomes we also include follow-up and interim results of ongoing clinical trials. In summary, we give a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma.

 
  Keywords: Biomarkers, everolimus, renal cell cancer, sunitinib, temsirolimus, tyrosine kinase inhibitors, Confidence interval, Erythroblastic Leukemia Viral Oncogene Homolog, Metastatic renal cell carcinoma, Mammalian target of rapamycin, Rat sarcoma, Renal cell carcinoma, Vascular endothelial growth factor
  Affiliation: Research Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences - Semmelweis University 1st Dept. of Pediatrics, Bokay u. 53-54., Budapest H-1083.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers